BR112014016635B8 - composto, composição, e, uso de um composto - Google Patents

composto, composição, e, uso de um composto

Info

Publication number
BR112014016635B8
BR112014016635B8 BR112014016635A BR112014016635A BR112014016635B8 BR 112014016635 B8 BR112014016635 B8 BR 112014016635B8 BR 112014016635 A BR112014016635 A BR 112014016635A BR 112014016635 A BR112014016635 A BR 112014016635A BR 112014016635 B8 BR112014016635 B8 BR 112014016635B8
Authority
BR
Brazil
Prior art keywords
compound
alpha3
composition
polyhydroxybenzopyranoketone
prodrug
Prior art date
Application number
BR112014016635A
Other languages
English (en)
Other versions
BR112014016635B1 (pt
BR112014016635A8 (pt
BR112014016635A2 (pt
Inventor
Ding Hongxia
Li Jin
Meng Kun
Original Assignee
Beijing Shenogen Pharma Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Shenogen Pharma Group Ltd filed Critical Beijing Shenogen Pharma Group Ltd
Publication of BR112014016635A2 publication Critical patent/BR112014016635A2/pt
Publication of BR112014016635A8 publication Critical patent/BR112014016635A8/pt
Publication of BR112014016635B1 publication Critical patent/BR112014016635B1/pt
Publication of BR112014016635B8 publication Critical patent/BR112014016635B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)

Abstract

composto, composição, e, uso de um composto. são fornecidos um composto de poli- hidroxibenzopiranocetona que tem a estrutura conforme representada pela fórmula (i) e sal farmaceuticamente aceitável do mesmo ou sua pró-droga, e também composição farmacêutica que contém o composto. o composto pode ser usado para regular e controlar um novo receptor de estrogênio er-alfa3, e para prevenir e/ou tratar as doenças relacionadas com tumores mediados pelo receptor er-alfa3, como câncer de mama, leucemia e câncer hepático e semelhantes.
BR112014016635A 2012-01-13 2012-12-31 composto, composição, e, uso de um composto BR112014016635B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201210011031 2012-01-13
CN20120011031.8 2012-01-13
CN201210573072.6 2012-12-25
CN201210573072.6A CN103204838B (zh) 2012-01-13 2012-12-25 多羟基苯并吡喃酮类化合物的合成及其抗肿瘤作用
PCT/CN2012/088016 WO2013104263A1 (zh) 2012-01-13 2012-12-31 多羟基苯并吡喃酮类化合物的合成及其抗肿瘤作用

Publications (4)

Publication Number Publication Date
BR112014016635A2 BR112014016635A2 (pt) 2017-06-13
BR112014016635A8 BR112014016635A8 (pt) 2017-07-04
BR112014016635B1 BR112014016635B1 (pt) 2021-07-13
BR112014016635B8 true BR112014016635B8 (pt) 2021-08-24

Family

ID=48752268

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014016635A BR112014016635B8 (pt) 2012-01-13 2012-12-31 composto, composição, e, uso de um composto

Country Status (11)

Country Link
US (1) US9221781B2 (pt)
EP (1) EP2803665B1 (pt)
JP (1) JP6113751B2 (pt)
KR (1) KR102030207B1 (pt)
CN (1) CN103204838B (pt)
AU (1) AU2012365712B2 (pt)
BR (1) BR112014016635B8 (pt)
CA (1) CA2860999C (pt)
ES (1) ES2627316T3 (pt)
MX (1) MX364833B (pt)
WO (1) WO2013104263A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101784990B1 (ko) * 2016-01-13 2017-10-12 주식회사 파이브지티 얼굴인식을 이용한 홈 오토메이션 제어 시스템 및 그 방법
CN107216303B (zh) * 2016-07-15 2020-04-21 北京盛诺基医药科技股份有限公司 氟可拉定的合成方法
CN107216302B (zh) * 2016-07-15 2020-02-21 北京盛诺基医药科技股份有限公司 一种氟可拉定的合成方法
AU2017313753B2 (en) 2016-08-16 2022-01-27 The Trustees Of Columbia University In The City Of New York GABA(A) receptor modulators and methods to control airway hyperresponsiveness and inflammation in asthma
US10266510B2 (en) 2017-01-18 2019-04-23 King Abdulaziz University Antimicrobial and cytotoxic compounds and methods for treating cancer, a bacterial infection, and/or a fungal infection
CN108947949B (zh) * 2017-05-19 2022-08-19 泰州华元医药科技有限公司 抗焦虑氘代化合物及其医药用途
CN109020938A (zh) * 2018-08-17 2018-12-18 昆明龙津药业股份有限公司 一种杨梅素的制备方法
CN110054605A (zh) * 2019-05-31 2019-07-26 北京盛诺基医药科技有限公司 一种淫羊藿素中间体的制备方法
CN110092770A (zh) * 2019-05-31 2019-08-06 北京盛诺基医药科技有限公司 一种黄酮化合物中间体的制备方法
CN112569222A (zh) * 2020-12-31 2021-03-30 赣南医学院 三氟淫羊藿素在制备改善疼痛、肿胀及运动功能的药物中的应用
CN112851615B (zh) * 2021-01-21 2023-04-07 厦门大学 一种异戊烯基黄酮的制备及其作为治疗宫颈癌药物的应用
CN113717138B (zh) * 2021-10-21 2023-02-24 沈阳药科大学 一类氮芥类色原酮衍生物与应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1786864A (zh) 2004-12-10 2006-06-14 上海迪比特实业有限公司 一种计算机安全认证方法
JP2007332695A (ja) 2006-06-16 2007-12-27 Advanced Media Inc 電子錠装置及び音声認証ロッカーシステム
WO2008100977A2 (en) 2007-02-14 2008-08-21 N.V. Organon Carbamates therapeutic release agents as amidase inhibitors
CN101104611A (zh) * 2007-04-29 2008-01-16 殷正丰 一种3-甲氧基黄酮类化合物,其制备方法和应用
JP2011518174A (ja) * 2008-04-18 2011-06-23 シェノゲン ファーマ グループ リミテッド エストロゲン受容体に関連する疾患を処置するための化合物及び方法
CN102038673B (zh) * 2009-10-20 2012-07-25 北京珅奥基医药科技有限公司 羟基苯并吡喃酮类化合物在制备治疗白血病药物中的应用
CN102558164B (zh) 2010-12-31 2016-06-15 北京盛诺基医药科技有限公司 苯并吡喃酮类雌激素受体调节剂

Also Published As

Publication number Publication date
CA2860999A1 (en) 2013-07-18
US20150011618A1 (en) 2015-01-08
CN103204838B (zh) 2017-06-09
JP6113751B2 (ja) 2017-04-12
JP2015503596A (ja) 2015-02-02
BR112014016635B1 (pt) 2021-07-13
BR112014016635A8 (pt) 2017-07-04
EP2803665A4 (en) 2015-07-08
WO2013104263A1 (zh) 2013-07-18
ES2627316T3 (es) 2017-07-27
KR20140109498A (ko) 2014-09-15
CA2860999C (en) 2019-12-31
CN103204838A (zh) 2013-07-17
US9221781B2 (en) 2015-12-29
KR102030207B1 (ko) 2019-10-08
EP2803665B1 (en) 2017-05-10
MX364833B (es) 2019-05-08
AU2012365712B2 (en) 2017-04-20
EP2803665A1 (en) 2014-11-19
AU2012365712A1 (en) 2014-07-24
MX2014008526A (es) 2014-11-25
BR112014016635A2 (pt) 2017-06-13

Similar Documents

Publication Publication Date Title
BR112014016635B8 (pt) composto, composição, e, uso de um composto
BR112015032921A8 (pt) compostos de benzofuranila e benzoxazolila substituídos e utilizações dos mesmos
BR112018070859A2 (pt) degradantes da proteína de bet
CR20170116A (es) Compuestos que inhiben la proteina mcl-1
PE20151939A1 (es) 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante
CL2015001508A1 (es) Compuestos derivados de bencimidazol, antagonistas de receptores ep4; composicion farmaceutica; combinacion farmaceutica; uso para tratar y/o prevenir enfermedades tales como endometriosis, hemorragias uterinas, dismenorrea, canceres de pulmon, de intestino, de mama, de prostata, entre otros.
UY35590A (es) Nuevos compuestos para el tratamiento del cáncer
CL2008001047A1 (es) Compuestos derivados de difenil-dihidro-imidazopiridinonas; inhibidores de mdm2-p53;composicion farmaceutica;y uso para preparar un medicamento destinado al tratamiento o control de tumores solidos,tales como:tumores de mama.de colon,de pulmon o de prostata.
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
MX2015012456A (es) Compuestos heterociclicos y usos de los mismos.
BR112013002220A2 (pt) derivado de ftalazinona cetona, método de prepração do mesmo, e uso farmacêutico do mesmo
MX2016007128A (es) Compuestos del receptor 6 de quimiocina (ccr6).
BR112012029647A2 (pt) novos derivados de pirimidinas
BR112017018305A2 (pt) desacetoxitubulisina h e análogos da mesma
MX2016015420A (es) Sales de dasatinib.
CO2018007112A2 (es) Composiciones farmacéuticas que comprenden derivados de fenilaminopirimidina
BR112019002560A2 (pt) composto, composição farmacêutica, uso de um composto, e, método
NZ721780A (en) Heterocyclic modulators of lipid synthesis for use against cancer and viral infections
BR112015028876A2 (pt) derivados de perhidroquinoxalina
MX369473B (es) Derivado de indolona sustituido por pirrol, método de preparación del mismo, composición que comprende el mismo y uso del mismo.
BR112015021097A2 (pt) formulações de compostos orgânicos
TR201819805T4 (tr) Flavaglin türevleri̇.
UA112746C2 (uk) Протиракові стероїдні лактони, ненасичені в положенні 7(8)
MX2015012600A (es) Compuestos de tetrahidroisoquinolina-2-il-(quinazolina-4-il) metanona como inhibidores del crecimiento de células cancerígenas.
EA201891866A1 (ru) N,N-ДИМЕТИЛ-3-[[5-(3-МЕТИЛ-2-ОКСО-1-ТЕТРАГИДРОПИРАН-4-ИЛ-ИМИДАЗО[4,5-c]ХИНОЛИН-8-ИЛ)-2-ПИРИДИЛ]ОКСИ]ПРОПАН-1-АМИНОКСИД В КАЧЕСТВЕ МОДУЛЯТОРА АТМ-КИНАЗЫ (МУТАЦИИ АТАКСИИ-ТЕЛЕАНГИЭКТАЗИИ) ДЛЯ ЛЕЧЕНИЯ РАКА

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 31/12/2012, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2636 DE 13/07/2021 QUANTO AO PRIORIDADE UNIONISTA.